

Datasheet: HCA256

Description:	HUMAN ANTI TOCILIZUMAB
Specificity:	TOCILIZUMAB
Other names:	ACTEMRA®, ROACTEMRA®
Format:	Purified
Product Type:	Monoclonal Antibody
Clone:	AbD21345_hlgG1
Isotype:	IgG1
Quantity:	0.1 mg

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
ELISA	▪			

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

Product Form

Human IgG1 antibody (lambda light chain) selected from the HuCAL phage display library and expressed in a human cell line. This antibody is supplied as a liquid.

Preparation

Purified IgG prepared by affinity chromatography on Protein A.

Buffer Solution

Phosphate buffered saline.

Preservative Stabilisers

0.01% Thiomersal.

Approx. Protein Concentrations

Antibody concentration 0.5 mg/ml.

Immunogen

Tocilizumab

Specificity

Human Anti-Tocilizumab Antibody, clone AbD21345_hlgG1 is a paratope specific, anti-idiotypic antibody that binds to free tocilizumab but not to human Interleukin-6

Receptor (IL-6R) or the drug/IL-6R complex.

Clone AbD21345_hlgG1 is a fully human recombinant monoclonal antibody with IgG1 isotype and is suitable as a surrogate positive control or calibrator (low affinity) in an anti-drug antibody (ADA) assay.

Tocilizumab (RoActemra/Actemra) is a humanized IgG1/kappa monoclonal antibody approved for the treatment of moderate to severe rheumatoid arthritis and for the treatment of systemic juvenile idiopathic arthritis. The therapeutic antibody is directed against IL-6R and acts by blocking the binding of IL-6R (both the soluble form, sIL-6R, and the membrane bound form, mIL-6R) to IL-6, thus impeding the pro-inflammatory properties of this cytokine.

[View a summary of all anti-tocilizumab antibodies](#)

Affinity	The intrinsic affinity of the monovalent form of this antibody is $K_D = 15$ nM as measured by real time, label free molecular interaction analysis on immobilized tocilizumab.
ELISA	This product may be used in a direct ELISA or as a detection reagent in a bridging ELISA together with HCA252 as the capture reagent. Protocol: PK bridging ELISA to measure free drug . This antibody is fully human and can be used as a reference standard in an ADA assay. Protocol: ADA bridging ELISA .
Storage	This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C. Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended.
Guarantee	12 months from date of despatch.
Acknowledgements	This product and/or its use is covered by claims of U.S. patents, and/or pending U.S. and non-U.S. patent applications owned by or under license to Bio-Rad Laboratories, Inc. See bio-rad.com/en-us/trademarks for details. Actemra and RoActemra are registered trademarks of Hoffman-La Roche and Chugai Pharmaceuticals co., Ltd.
Health And Safety Information	Material Safety Datasheet documentation #10094 available at: 10094: https://www.bio-rad-antibodies.com/uploads/MSDS/10094.pdf
Licensed Use	For <i>in vitro</i> research purposes and for commercial applications for the provision of <i>in vitro</i> testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.
Regulatory	For research purposes only.

Technical Advice Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the [HuCAL Antibodies Technical Manual](#).

Related Products

Recommended Useful Reagents

[HUMAN ANTI TOCILIZUMAB \(HCA252\)](#)

[LYNX RAPID HRP ANTIBODY CONJUGATION KIT \(LNK001P\)](#)

[LYNX RAPID HRP ANTIBODY CONJUGATION KIT \(LNK002P\)](#)

[LYNX RAPID HRP ANTIBODY CONJUGATION KIT \(LNK003P\)](#)

[LYNX RAPID HRP ANTIBODY CONJUGATION KIT \(LNK004P\)](#)

[LYNX RAPID HRP ANTIBODY CONJUGATION KIT \(LNK005P\)](#)

[LYNX RAPID HRP ANTIBODY CONJUGATION KIT \(LNK006P\)](#)

[HISPEC ASSAY DILUENT \(BUF049A\)](#)

[HUMAN ANTI TOCILIZUMAB \(HCA253\)](#)

[HUMAN ANTI TOCILIZUMAB \(HCA254\)](#)

[HUMAN ANTI TOCILIZUMAB \(HCA255\)](#)

[HUMAN ANTI TOCILIZUMAB \(HCA257\)](#)

North & South Tel: +1 800 265 7376

America Fax: +1 919 878 3751

Email: antibody_sales_us@bio-rad.com

Worldwide

Tel: +44 (0)1865 852 700

Fax: +44 (0)1865 852 739

Email: antibody_sales_uk@bio-rad.com

Europe

Tel: +49 (0) 89 8090 95 21

Fax: +49 (0) 89 8090 95 50

Email: antibody_sales_de@bio-rad.com

To find a batch/lot specific datasheet for this product, please use our online search tool at: bio-rad-antibodies.com/datasheets

'M406616:220927'

Printed on 27 Sep 2022

© 2022 Bio-Rad Laboratories Inc | [Legal](#) | [Imprint](#)